+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

This study aims to collect prospective safety and effectiveness data for the C-Brace System, a microprocessor-controlled knee ankle foot orthosis, following standard care practices. The research focuses on patients with lower extremity pareses who are fitted with the C-Brace device. The goal is to better understand how the C-Brace influences walking speed, balance, risk of falling, and confidence in balance over time. The C-Brace is a custom-made device with thigh, calf, and foot components connected by an ankle joint or spring element. It uses sensors to continuously monitor knee joint movement and walking phases, adjusting hydraulic resistance and knee motion accordingly. Patients enrolled in the registry will undergo baseline evaluation, fitting, training or therapy sessions, and follow-up visits at 6, 12, 24, and 36 months after fitting. Participants will be assessed through various tests including timed walk tests, balance confidence scores, and mobility assessments at different intervals. The study also tracks falls related to device use and changes in activity levels with an activity tracker. Data collected will help characterize the safety and functional impact of the C-Brace over three years of follow-up.

All AgesAll Genders
76 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating ARQ-234, a subcutaneous injectable solution, in a first-in-human, Phase 1, double-blind, randomized, placebo-controlled study. The study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ-234 in both healthy volunteers and participants with moderate to severe atopic dermatitis AD. The research includes multiple parts with staggered starts to understand effects in different participant groups. The study consists of three parts Part A involves single ascending dose SAD cohorts with healthy volunteers and AD participants Part B includes multiple ascending dose MAD cohorts with AD participants and Part C is a proof-of-concept expansion in AD participants. Participants receive ARQ-234 or placebo via subcutaneous injection, with dosing and escalation schedules varying by cohort. Each part evaluates increasing doses to study safety and drug behavior. Participants will be involved in screening, dosing, and follow-up visits lasting up to 16 weeks for Part A and up to 30 weeks for Parts B and C. Assessments include adverse event monitoring, disease severity scoring using the Eczema Area and Severity Index EASI, body surface area affected, itch severity, SCORAD, POEM, and Investigators Global Assessment scores. Blood samples will be collected to study drug concentrations. Safety evaluations, questionnaires, and clinical exams will monitor participants throughout the study.

Age: 18Years - 65YearsAll GendersPhase 1
7 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 1 clinical trial to study the safety, tolerability, pharmacokinetics, and pharmacodynamics of CAY001, a drug given intravenously. This first-in-human, randomized, double-blind, placebo-controlled study involves healthy male and female volunteers aged 18 to 50 years. The goal is to better understand how CAY001 behaves in the body and how safe it is at different dose levels. Participants will be randomly assigned to receive either CAY001 or a placebo. The study will test three different dose levels of CAY001 given as a single ascending dose to groups of subjects. Approximately 24 healthy volunteers will take part in this study. Each participant will be closely monitored during and after dosing to evaluate the effects and how the drug is processed in the body. During the study, researchers will perform physical exams, vital sign checks, electrocardiograms ECGs, blood and urine tests, and other laboratory assessments to track changes from the start of the study through 28 days after dosing. Safety will be carefully monitored by recording any adverse events and changes in various health parameters. Pharmacokinetic measurements will also be taken up to 24 hours after dosing to understand the drugs behavior. Participants will be involved in scheduled visits and assessments throughout the study period to ensure their well-being and to collect necessary data.

Age: 18Years - 50YearsAll GendersPhase 1
1 location